/Bill Kelly

About Bill Kelly

This author has not yet filled in any details.
So far Bill Kelly has created 815 blog entries.

Angel investment tax credit bill headed for Governor

A bill that expands Connecticut's angel investor tax credit program to businesses in any industry has unanimously passed the Senate. Scheduled to go into effect July 1, if approved by the governor, House Bill 5583 would open up the program beyond already specified technology industries. more

By |June 16th, 2017|News|0 Comments

Susan Froshauer to leave CURE in October

Dear Colleagues, This is to announce that after four great years, I will resign my positions as the President and CEO of CURE and President of The CURE Innovation Commons, effective October 1, 2017. After giving the matter careful consideration, I feel that this is the right time for me to be moving on to other projects that will engage the same level of passion and community building that we at CURE have been fostering. I look forward to the challenges ahead. But what an honor and pleasure it has been to work with so many friends and professionals on [...]

By |June 16th, 2017|News|0 Comments

Bill re microbiome plan will go to CT Governor

On its final day of session, the Connecticut House passed S.B. 1056, AN ACT ESTABLISHING A WORKING GROUP TO DEVELOP A PLAN TO FOSTER THE MICROBIOME SECTOR IN THE STATE. The bill will now go to the Governor for his consideration and signature. Among other provisions, the bill would create a working group to identify companies focused on microbiome science that are in early stage development and develop tools and financial incentives, including, but not limited to, sponsoring an annual competition for start-up microbiome companies and early stage research projects to recruit such companies to locate in or pursue such [...]

By |June 16th, 2017|News|0 Comments

Dr. Todd E. Arnold to join CURE Board of Directors

We are pleased to announce the election of Dr. Todd E. Arnold to CURE's Board of Directors. Todd was recently named Chief Laboratory Operations Officer for Sema4, the spinout company of the Mount Sinai Health System formed by Mount Sinai and Eric Schadt. Prior to his role at Sema4, Todd was the Managing Director of the Mount Sinai Genetic Testing Laboratory–Connecticut, a state of the art, high throughput nucleic acid sequencing facility. Todd currently serves on the CURE Government Affairs Committee and has devoted special effort to the cultivation and retention of scientific and technical talent in Connecticut. biography CURE [...]

By |June 16th, 2017|News|0 Comments

Four CT ‘Innovation Places’ to receive grants in 2018

CT Next has designated four Innovation Places that will receive implementation grants in 2018. The four are: Hartford/East Hartford (led by Hartford/East Hartford Innovation Places Initiative) New Haven (led by Elm City Innovation Collaborative) New London/Groton (led by Thames River Innovation Place) Stamford (led by Innovate Stamford) The Thames River Innovation Place includes CURE Innovation Commons, the newly designed office and laboratory facility in Groton. “The Innovation Places program brought out the best in each community and provided a unique opportunity for the public and private sector to work across silos and think about how to collectively enhance their community’s [...]

By |June 16th, 2017|News|0 Comments

Pfizer advances re breast cancer, lung cancer

Pfizer has presented data showing that its investigational, dual-mechanism poly ADP ribose polymerase (PARP) inhibitor, talazoparib, demonstrated anti-tumor activity in patients with germline (inherited) BRCA1/2-positive (gBRCA+) advanced breast cancer ... more In the lung cancer space, Pfizer's dacomitinib has slowly emerged as a contender, and becoming the first second-generation kinase inhibitor to report Phase 3 data should improve its profile ... more

By |June 16th, 2017|News|0 Comments

Melinta to present at New Orleans meeting

Melinta Therapeutics will make five presentations of clinical, in vitro and pharmacokinetic results from studies of Baxdela™ (delafloxacin), an investigational anionic fluoroquinolone, at the ASM Microbe 2017 meeting. In addition there will be an oral presentation on the potential of RX-P2177, a novel pyrrolocytosine antibiotic developed internally as part of the ESKAPE pathogen program that uses a proprietary ribosome-targeting platform.  RX-P2177 shows promising activity for the treatment of gonorrhea. ASM Microbe 2017 will take place June 1–5, 2017 in New Orleans, LA. more

By |June 16th, 2017|News|0 Comments

CT bill affects entrepreneurship and investment

The Connecticut Senate has passed S.B. No. 1051, AN ACT CONCERNING CTNEXT PLANNING GRANTS-IN-AID AND INNOVATION PLACE DESIGNATION APPLICATIONS, INVEST CT FUND TAX CREDIT TRANSFERABILITY AND STATE INVESTMENTS WITH VENTURE CAPITAL FIRMS. This bill makes the following changes to various entrepreneurship and investment programs: 1. allows CTNext, a Connecticut Innovations subsidiary, to accept additional rounds of innovation place applications and planning grant applications (§ 1); 2. allows insurance companies who hold Invest CT tax credits to sell or otherwise transfer those credits to any taxpayer, rather than just to their affiliates, and makes a conforming change (§§ 2 & 3); and [...]

By |June 16th, 2017|News|0 Comments

Alexion announces additions to leadership team

Alexion Pharmaceuticals has announced key additions to its executive leadership team effective June 5, 2017. Reporting to Chief Executive Officer Ludwig Hantson will be: John Orloff, M.D., Executive Vice President, Head of Research & Development; Anne-Marie Law, Executive Vice President, Chief Human Resources Officer; and Indrani Lall Franchini, J.D., Executive Vice President, Chief Compliance Officer. “These highly talented executives brings deep industry experience and a proven track record in their respective areas of expertise,” Hanston said. more

By |June 16th, 2017|News|0 Comments

Intensity Therapeutics begins treating patients

Intensity Therapeutics, Inc., a privately held biotechnology company based in Westport, has announced that the first patient successfully received treatment with the Company’s lead product, INT230-6, as part of a Phase 1/2 international clinical study. “Bringing our novel product into human testing is a major milestone,” commented President and CEO Lewis H. Bender. “Over the past few years our Company has demonstrated impressive tumor shrinkage in several murine models of cancers. INT230-6 eradicated large tumors, activated a systemic immune response and improved survival.” more

By |June 16th, 2017|News|0 Comments